Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproTSE:8086 +0.39%70 EBITDA Margin % is 39.15% as of Mar. 2026, which is 172% above its 10-year median of 14.39. GuruFocus rates TSE:8086 with a GF Score™ of 70/100 and a GF Value™ of 円1,457.04 (Fairly Valued). The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Nipro ranks better than 67.2% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nipro's EBITDA for the
three
months ended in Mar. 2026 was 円67,813 Mil. Nipro's Revenue for the
three
months ended in Mar. 2026 was 円173,233 Mil. Therefore, Nipro's EBITDA margin for the quarter that ended in Mar. 2026 was 39.15%.
Nipro (TSE:8086) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nipro EBITDA Margin % Related Terms
Nipro EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nipro's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:8086 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nipro's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nipro's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (TSE:8086) has a EBITDA Margin % of 39.15% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nipro and its competitors. This is 172% above median its historical median of 14.39. Over the past decade, Nipro's EBITDA Margin % has ranged from 7.94 to 15.61. According to the industry distribution chart, Nipro ranks #268 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 32.8%.
Is Nipro's EBITDA Margin % too high?
Nipro's current EBITDA Margin % of 39.15% is 172% above median its 10-year median of 14.39. Over the past 10 years, this metric has ranged from a low of 7.94 to a high of 15.61. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Nipro's value of 39.15% is 426.2% above this industry median. Based on the distribution chart, Nipro ranks #268 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nipro has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #268 out of 817 companies for EBITDA Margin %. This puts Nipro in the upper half of its industry. The industry median EBITDA Margin % is 7.44. Nipro's value of 39.15% is 426.2% above this benchmark. Historically, Nipro's own EBITDA Margin % has ranged from 7.94 to 15.61 over the past decade. While the company's 10-year median is 14.39 vs. the industry median of 7.44, Nipro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nipro's current EBITDA Margin % of 39.15% is 426.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nipro and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current EBITDA Margin % is 39.15%, which is 172% above median its own 10-year median of 14.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,457.04, compared to a current price of 円1,552.50 — trading 6.6% above its estimated fair value. The current EBITDA Margin % is 39.15%, which is 172% above median its 10-year median of 14.39 and 426.2% above the Medical Devices & Instruments industry median of 7.44. Nipro's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nipro (TSE:8086), the current EBITDA Margin % is 39.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,552.50 is trading 6.6% above its estimated GF Value™ of 円1,457.04.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
EBITDA Margin %: 39.15% (172% above median its 10-year median of 14.39)
GF Value™: 円1,457.04 vs. price of 円1,552.50 (6.6% above fair value)
Industry Position: 426.2% above the Medical Devices & Instruments median (#268 of 817)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
70GF Score
Get the complete analysis for TSE:8086
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
